A detailed history of Los Angeles Capital Management LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 10,501 shares of SAGE stock, worth $60,170. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,501
Previous 10,501 -0.0%
Holding current value
$60,170
Previous $114,000 34.21%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 05, 2024

SELL
$10.58 - $17.9 $51,281 - $86,761
-4,847 Reduced 31.58%
10,501 $114,000
Q4 2023

Feb 06, 2024

BUY
$17.1 - $22.26 $262,450 - $341,646
15,348 New
15,348 $332,000
Q2 2022

Aug 05, 2022

SELL
$27.52 - $37.99 $358,585 - $495,009
-13,030 Closed
0 $0
Q1 2022

May 06, 2022

BUY
$30.71 - $45.71 $400,151 - $595,601
13,030 New
13,030 $431,000
Q2 2019

Jul 29, 2019

SELL
$157.85 - $183.09 $1.31 Million - $1.52 Million
-8,321 Closed
0 $0
Q1 2019

Apr 25, 2019

BUY
$89.33 - $163.65 $743,314 - $1.36 Million
8,321 New
8,321 $1.32 Million
Q4 2018

Feb 11, 2019

SELL
$81.94 - $139.71 $128,645 - $219,344
-1,570 Closed
0 $0
Q3 2018

Nov 05, 2018

SELL
$138.11 - $169.04 $12.1 Million - $14.8 Million
-87,686 Reduced 98.24%
1,570 $222,000
Q2 2018

Jul 31, 2018

BUY
$140.36 - $175.76 $8.15 Million - $10.2 Million
58,069 Added 186.2%
89,256 $14 Million
Q1 2018

Apr 27, 2018

BUY
$152.15 - $192.33 $4.27 Million - $5.4 Million
28,087 Added 906.03%
31,187 $5.02 Million
Q4 2017

Feb 05, 2018

SELL
$60.72 - $167.34 $21,252 - $58,569
-350 Reduced 10.14%
3,100 $511,000
Q3 2017

Nov 06, 2017

BUY
$61.4 - $88.52 $211,830 - $305,394
3,450
3,450 $215,000

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $340M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.